Axonis Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 32

Axonis Therapeutics General Information

Description

Operator of a neuro-focused biotechnology company intended to develop medicines targeting a critical mediator of inhibitory neurotransmission in the brain. The company has developed a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery platform, enabling the healthcare industry to develop treatments for neurological disorders such as epilepsy, pain, and other central nervous system conditions.

Contact Information

Website
www.axonis.us
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 75 Kneeland Street
  • 14th Floor
  • Boston, MA 02111
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 75 Kneeland Street
  • 14th Floor
  • Boston, MA 02111
  • United States

Axonis Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axonis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
18. Accelerator/Incubator Completed Clinical Trials - Phase 1
17. Later Stage VC (Series A) 30-Oct-2024 Completed Clinical Trials - Phase 1
16. Accelerator/Incubator 01-Oct-2024 Completed Pre-Clinical Trials
15. Seed Round 22-Mar-2024 Completed Pre-Clinical Trials
14. Grant 01-Jan-2023 Completed Pre-Clinical Trials
13. Grant 24-Sep-2022 Completed Pre-Clinical Trials
12. Grant 01-Sep-2022 Completed Pre-Clinical Trials
11. Seed Round 10-Aug-2022 Completed Pre-Clinical Trials
10. Accelerator/Incubator 15-Jul-2022 $9.6M Completed Pre-Clinical Trials
9. Seed Round 28-Jun-2021 $5M $9.6M Completed Pre-Clinical Trials
To view Axonis Therapeutics’s complete valuation and funding history, request access »

Axonis Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed-3
Seed-2
Seed-1
Seed Acceleration 9,345,782 $0.000100 6% $1.18 $1.18 1x $1.18 7.65%
Seed 1,067,536 $0.000100 6% $3.56 $3.56 1x $3.56 0.87%
To view Axonis Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Axonis Therapeutics Patents

Axonis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026207340-A1 Kcc2 potentiators and uses thereof Pending 28-Mar-2025
WO-2026193233-A1 Kcc2 potentiators and uses thereof Pending 12-Mar-2025
WO-2026174141-A1 Kcc2 potentiators and uses thereof Pending 14-Feb-2025
WO-2026174141-A8 Kcc2 potentiators and uses thereof Pending 14-Feb-2025
WO-2026136888-A1 Fused azines as kcc2 potentiators and uses thereof Pending 20-Dec-2024 C07D487/04
To view Axonis Therapeutics’s complete patent history, request access »

Axonis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axonis Therapeutics Investors (32)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cormorant Asset Management PE/Buyout Minority
Hatteras Venture Partners Venture Capital Minority
Lumira Ventures Venture Capital Minority
MRL Ventures Fund Corporate Venture Capital Minority
Perceptive Advisors Venture Capital Minority
You’re viewing 5 of 32 investors. Get the full list »

Axonis Therapeutics FAQs

  • When was Axonis Therapeutics founded?

    Axonis Therapeutics was founded in 2019.

  • Where is Axonis Therapeutics headquartered?

    Axonis Therapeutics is headquartered in Boston, MA.

  • What is the size of Axonis Therapeutics?

    Axonis Therapeutics has 21 total employees.

  • What industry is Axonis Therapeutics in?

    Axonis Therapeutics’s primary industry is Drug Discovery.

  • Is Axonis Therapeutics a private or public company?

    Axonis Therapeutics is a Private company.

  • What is Axonis Therapeutics’s current revenue?

    The current revenue for Axonis Therapeutics is .

  • How much funding has Axonis Therapeutics raised over time?

    Axonis Therapeutics has raised $150M.

  • Who are Axonis Therapeutics’s investors?

    Cormorant Asset Management, Hatteras Venture Partners, Lumira Ventures, MRL Ventures Fund, and Perceptive Advisors are 5 of 32 investors who have invested in Axonis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process